JP4703567B2 - 膠細胞起源の腫瘍の診断と治療のための組成物と方法 - Google Patents

膠細胞起源の腫瘍の診断と治療のための組成物と方法 Download PDF

Info

Publication number
JP4703567B2
JP4703567B2 JP2006533319A JP2006533319A JP4703567B2 JP 4703567 B2 JP4703567 B2 JP 4703567B2 JP 2006533319 A JP2006533319 A JP 2006533319A JP 2006533319 A JP2006533319 A JP 2006533319A JP 4703567 B2 JP4703567 B2 JP 4703567B2
Authority
JP
Japan
Prior art keywords
antibody
tat
polypeptide
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006533319A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007516232A (ja
JP2007516232A5 (enExample
Inventor
ハイディ フィリップス，
Original Assignee
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネンテック， インコーポレイテッド filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2007516232A publication Critical patent/JP2007516232A/ja
Publication of JP2007516232A5 publication Critical patent/JP2007516232A5/ja
Application granted granted Critical
Publication of JP4703567B2 publication Critical patent/JP4703567B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2006533319A 2003-05-23 2004-05-21 膠細胞起源の腫瘍の診断と治療のための組成物と方法 Expired - Fee Related JP4703567B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US47323803P 2003-05-23 2003-05-23
US60/473,238 2003-05-23
US54829904P 2004-02-27 2004-02-27
US60/548,299 2004-02-27
PCT/US2004/016121 WO2004112829A2 (en) 2003-05-23 2004-05-21 Compositions and methods for the diagnosis and treatment of tumors of glial origin

Publications (3)

Publication Number Publication Date
JP2007516232A JP2007516232A (ja) 2007-06-21
JP2007516232A5 JP2007516232A5 (enExample) 2007-08-02
JP4703567B2 true JP4703567B2 (ja) 2011-06-15

Family

ID=33544287

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533319A Expired - Fee Related JP4703567B2 (ja) 2003-05-23 2004-05-21 膠細胞起源の腫瘍の診断と治療のための組成物と方法

Country Status (9)

Country Link
US (2) US20050112129A1 (enExample)
EP (1) EP1628679A2 (enExample)
JP (1) JP4703567B2 (enExample)
KR (1) KR20060015296A (enExample)
AU (1) AU2004249125A1 (enExample)
CA (1) CA2524567A1 (enExample)
MX (1) MXPA05012613A (enExample)
NZ (1) NZ543751A (enExample)
WO (1) WO2004112829A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
NZ533933A (en) * 2002-01-02 2008-06-30 Genentech Inc Compositions and methods for the diagnosis and treatment of glioma tumor
WO2004106495A2 (en) 2003-05-29 2004-12-09 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US7473531B1 (en) * 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
US7824685B2 (en) * 2004-01-26 2010-11-02 Baylor College Of Medicine RTVP based compositions and methods for the treatment of prostate cancer
WO2006077941A1 (ja) * 2005-01-19 2006-07-27 Keio University 癌ワクチン
WO2007012937A2 (en) * 2005-07-26 2007-02-01 Council Of Scientific And Industrial Research Method for diagnosis of glioma distinguishing between progressive and denovo types
ES2330904B1 (es) * 2005-09-21 2010-09-23 Fundacio Centre De Recerca En Sanitat Animal Polinucleotidos de haemophilus parasuis y su uso.
US7482131B2 (en) * 2005-11-15 2009-01-27 United States Department Of Veterans Affairs Detection of PKC-iota as a biomarker for brain tumorigenesis
ES2392103T3 (es) * 2006-03-13 2012-12-04 Novovacs Holding B.V. Vacuna contra el cáncer
WO2008067351A2 (en) * 2006-11-29 2008-06-05 Genentech, Inc. Method of diagnosing and treating glioma
US20090011060A1 (en) * 2007-07-06 2009-01-08 Peter Koepke Campsiandra angustifolia extract and methods of extracting and using such extract
WO2009017833A2 (en) 2007-08-02 2009-02-05 Arresto Biosciences Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
MX2010001378A (es) 2007-08-03 2010-06-02 Facet Biotech Corp Uso terapeutico de anticuerpos del receptor anti-tweak.
US7879369B2 (en) 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
EP2271770B1 (en) * 2008-03-31 2018-08-22 Genentech, Inc. Compositions and methods for treating and diagnosing asthma
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
EP2216399A1 (en) 2009-01-30 2010-08-11 Université de la Méditerranée Human soluble CD146, preparation and uses thereof
EP2467714A4 (en) * 2009-08-21 2013-02-20 Gilead Biologics Inc IN VITRO SCREENING ASSAYS
WO2011022667A2 (en) 2009-08-21 2011-02-24 Arresto Biosciences, Inc Catalytic domains from lysyl oxidase and loxl2
EP2531217A4 (en) 2010-02-04 2013-11-27 Gilead Biologics Inc ANTIBODIES THAT BIND TO LOXL2 (LYSYL OXIDASE-LIKE 2) AND METHODS OF USE THEREOF
MA34291B1 (fr) * 2010-05-03 2013-06-01 Genentech Inc Compositions et méthodes de diagnostic et de traitement d'une tumeur
WO2012061120A1 (en) * 2010-10-25 2012-05-10 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
WO2012083132A2 (en) 2010-12-16 2012-06-21 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
CA3012006A1 (en) * 2017-07-31 2019-01-31 Modern Meadow, Inc. Yeast strains and methods for controlling hydroxylation of recombinant collagen
CN120569400A (zh) * 2022-11-14 2025-08-29 德克萨斯大学系统董事会 使用硝化抗性ccl2趋化因子的组合物和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
US6518061B1 (en) * 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5614191A (en) 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6150162A (en) 1998-12-17 2000-11-21 Isis Pharmaceuticals Inc. Antisense modulation of CD44 expression
WO2000064946A2 (en) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
US6960651B2 (en) * 1999-06-29 2005-11-01 Millennium Pharmaceuticals, Inc. TANGO 332 polypeptides
WO2001036685A2 (en) 1999-11-17 2001-05-25 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
JP2005536439A (ja) * 2001-09-18 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断及び治療のための組成物と方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Also Published As

Publication number Publication date
WO2004112829A2 (en) 2004-12-29
US20070231323A1 (en) 2007-10-04
EP1628679A2 (en) 2006-03-01
NZ543751A (en) 2008-05-30
US20050112129A1 (en) 2005-05-26
AU2004249125A1 (en) 2004-12-29
WO2004112829A3 (en) 2005-03-31
JP2007516232A (ja) 2007-06-21
MXPA05012613A (es) 2006-05-25
KR20060015296A (ko) 2006-02-16
US8008004B2 (en) 2011-08-30
CA2524567A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
JP4822710B2 (ja) 腫瘍の診断と治療のための組成物と方法
JP4912356B2 (ja) 腫瘍の診断及び治療のための組成物及び方法
JP4703567B2 (ja) 膠細胞起源の腫瘍の診断と治療のための組成物と方法
US7767403B2 (en) Compositions and methods for the diagnosis and treatment of tumor
JP5587841B2 (ja) 造血系起源の腫瘍の治療のための組成物と方法
US20050064492A1 (en) Compositions and methods for the diagnosis and treatment of tumor
US20070048218A1 (en) Compositions and Methods for the Diagnosis and Treatment of Tumor
US20070224201A1 (en) Compositions and methods for the diagnosis and treatment of tumor
JP2008137989A (ja) 腫瘍の診断と治療のための組成物と方法
JP2006516192A (ja) 腫瘍の診断と治療のための組成物と方法
JP4658967B2 (ja) 造血系起源の腫瘍の治療のための組成物と方法
JP2007521791A (ja) 腫瘍の診断と治療のための組成物と方法
US20080096215A1 (en) Compositions and methods for the diagnosis and treatment of tumor
US20070098634A1 (en) Compositions and methods for the diagnosis and treatment of tumor
JP2007077155A (ja) 腫瘍の診断と治療のための組成物と方法
US20060140961A1 (en) Compositions and methods for the diagnosis and treatment of tumor
US20070041983A1 (en) Method for treating tumors using anti-osteopontin antibodies
JP2005513084A (ja) 腫瘍の診断と治療のための組成物及び方法
JP2011019523A (ja) 造血系起源の腫瘍の治療のための組成物と方法
JP2005523311A (ja) 腫瘍の診断と治療のための組成物と方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101020

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101122

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101220

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110308

LAPS Cancellation because of no payment of annual fees